Related Experiment Video
Updated: Jan 8, 2026
08:31
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
530
A Phase II Study of Bendamustine Plus Rituximab in Patients with Relapsed or Progressive Marginal Zone Lymphoma: KCSG
Jeong-Ok Lee1, Jinny Park2, Hye Jin Kang3
1Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Cancer Research and Treatment
|December 11, 2025
Summary
Bendamustine plus rituximab showed high efficacy in treating relapsed or progressive marginal zone lymphoma (MZL). This combination therapy provided durable disease control with manageable safety profiles in patients with MZL.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Marginal zone lymphoma (MZL) is a heterogeneous group of non-Hodgkin lymphomas.
- Relapsed or progressive MZL often requires effective and tolerable treatment options.
Purpose of the Study:
- To evaluate the efficacy and safety of bendamustine plus rituximab in patients with relapsed or progressive MZL.
- To determine the overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) of this treatment regimen.
Main Methods:
- A multicenter, phase II study was conducted.
- Patients received bendamustine and rituximab over six cycles.
- Dose reductions were permitted based on toxicity criteria.
Main Results:
- An 81.8% overall response rate (ORR) was observed, with 40.7% complete responses.
- Median progression-free survival (PFS) was 46.06 months; 3-year overall survival (OS) was 92.3%.
- Hematological toxicities, particularly neutropenia (48.1%), were most common, leading to dose modifications.
Conclusions:
- Bendamustine plus rituximab is a highly effective treatment for relapsed or progressive MZL.
- The regimen offers durable disease control with a tolerable safety profile.
- This combination represents a valuable therapeutic option for patients with relapsed/progressive MZL.
